Skip to main content
SpringerLink
Log in

Angiotensin Converting Enzyme Inhibition with Quinapril and Left Ventricular Mass in the Hypertensive Patient

A 4-Month Echocardiographic Study

  • Original Research Article
  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

The effects of quinapril (an angiotensin converting enzyme inhibitor) on cardiac hypertrophy were evaluated in a noncomparative study of 98 patients with mild to moderate hypertension over 4 months. Left ventricular hypertrophy (LVH) was diagnosed using echocardiography in 60% of patients at baseline. Combination therapy with hydrochlorothiazide (HCTZ) was initiated after 1 month in patients with inadequate blood pressure control to achieve a target diastolic pressure reduction from baseline (≥ 10mm Hg) and/or reduction to < 90mm Hg. Left ventricular mass index (LVMI) was significantly reduced for patients of either sex with a baseline diagnosis of LVH, but not for those in whom LVH was not detected at enrolment. Systolic and diastolic blood pressures were also significantly reduced. The response rate was 83%, while 28% of patients required combination therapy with HCTZ. There was no correlation between the hypotensive effects of quinapril and change in LVMI. Furthermore, the addition of a diuretic did not appear to affect the LVMI response. Thus, the amelioration of LVH noted in this investigation appears to be attributable to quinapril.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969; 71: 89–105

    PubMed  CAS  Google Scholar 

  2. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocar-diographic left ventricular hypertrophy and risk of coronary artery disease: the Framingham study. Ann Intern Med 1970; 72: 813–22

    PubMed  CAS  Google Scholar 

  3. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the Hypertension Detection and Follow-up Program: I. Reduction of mortality of persons with high blood pressure, including mild hypertension. J Am Med Assoc 1979; 242: 2562–71

    Article  Google Scholar 

  4. Reichek N, Devereux RB. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardio-graphic findings. Circulation 1981; 63: 1391–8

    Article  PubMed  CAS  Google Scholar 

  5. Woythaler JN, Singer SL, Kwan OL, et al. Accuracy of echocardiography versus electrocardiography in detecting left ventricular hypertrophy: comparison with post-mortem mass measurement. J Am Coll Cardiol 1983; 2: 305–11

    Article  PubMed  CAS  Google Scholar 

  6. Hammond IW, Devereux RB, Alderman MH, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J American Coll Cardiol 1986; 7: 639–50

    Article  CAS  Google Scholar 

  7. Levy D, Anderson KM, Savage DD, et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108: 7–13

    PubMed  CAS  Google Scholar 

  8. Frolich ED, Chobanian AV, Devereux RB, et al. The heart in hypertension. N Eng J Med 1992; 327: 998–1008

    Article  Google Scholar 

  9. Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process. Am J Med 1980; 69: 576–84

    Article  PubMed  CAS  Google Scholar 

  10. Strauer BE. Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiology 1979; 44: 999–1006

    Article  CAS  Google Scholar 

  11. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173–8

    PubMed  CAS  Google Scholar 

  12. Kannel WB, Doyle JT, McNamara PM, et al. Precursors of sudden coronary death: factors related to the incidence of sudden death. Circulation 1975; 51: 606–13

    Article  PubMed  CAS  Google Scholar 

  13. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Eng J Med 1990; 322: 1561–6

    Article  CAS  Google Scholar 

  14. McLenachan JM, Henderson E, Morris KL, et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Eng J Med 1987; 317: 787–92

    Article  CAS  Google Scholar 

  15. Banas JS. Preliminary report of the efficacy and safety of quinapril in acute and chronic treatment of patients with congestive heart failure. Angiology 1989; 40: 396–404

    PubMed  Google Scholar 

  16. Holt P, Najm J, Sowton E. The acute hemodynamic effects of quinapril, a new non-sulphydryl angiotensin converting enzyme inhibitor, in patients with severe congestive heart failure. Eur J Clin Pharmacol 1986; 31: 9–14

    Article  PubMed  CAS  Google Scholar 

  17. Nieminen MS, Kupari M. The hemodynamic effects of ACE inhibitors in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1990; 15 Suppl. 2: S36–40

    Article  PubMed  Google Scholar 

  18. Gupta RK, Kjeldsen SE, Krause L, et al. Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 1990; 48: 41–9

    Article  PubMed  CAS  Google Scholar 

  19. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55: 613–8

    Article  PubMed  CAS  Google Scholar 

  20. Teichholtz L, Kreulen T, Herman M, Ganlin R. Problems in echocardiographic angiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976; 37: 7–11

    Article  Google Scholar 

  21. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 14

    Article  Google Scholar 

  22. Dubois EF. Basal metabolism in health and disease. Philadelphia: Lea & Febiger, 1936

    Google Scholar 

  23. Devereux RB, Lutas EM, Casale RN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222–30

    Article  PubMed  CAS  Google Scholar 

  24. Jones A, Davies DH, Dove JR, et al. Identification and treatment of risk factors for coronary heart disease in general practice: a possible screening model. BMJ 1988; 296: 1711–4

    Article  PubMed  CAS  Google Scholar 

  25. Grandi AM, Venco A, Barzizza F, et al. Double-blind comparison of Perindopril and Captopril in hypertension. Effects on left ventricular morphology and function. Am J Hypertens 1991; 4: 516–20

    PubMed  CAS  Google Scholar 

  26. Rizzoni D, Muiesan ML, Montani G, et al. Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring. Am J Hypertens 1992; 5: 180–6

    PubMed  CAS  Google Scholar 

  27. White WB. Assessment of patients with office hHypertens by 24hr non invasive ambulatory blood pressure monitoring. Arch Intern Med 1986; 146: 2196–9

    Article  PubMed  CAS  Google Scholar 

  28. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hHypertens, Circulation 1990; 81: 528–36

    Article  PubMed  CAS  Google Scholar 

  29. Dzau VJ, Re RN. Evidence of the existence of renin in the heart. Circulation 1987; 75 Suppl. I: I134–6

    PubMed  CAS  Google Scholar 

  30. Johnston CI, Jandeleit K, Mooser V, et al. Angiotensin-converting enzyme and its inhibition in the heart and blood vessels. J Cardiovasc Pharmacol 1992; 20 Suppl. B: S6–11

    Google Scholar 

  31. Kinoshita A, Urata H, Bumpus FM, et al. Measurement of angiotensin I converting enzyme inhibition in the heart. Circ Res 1993; 73: 51–60

    Article  PubMed  CAS  Google Scholar 

  32. Julius S, Li Y, Brandt D, et al. Quinapril, an angiotensin converting enzyme inhibitor, prevents cardiac hypertrophy during episodic hypertension. Hypertension 1991; 17: 1161–6

    Article  PubMed  CAS  Google Scholar 

  33. Drayer JL, Weber MA, DeYoung JL. BP as a determinant of cardiac left ventricular muscle mass. Arch Intern Med 1983; 143: 90–2

    Article  PubMed  CAS  Google Scholar 

  34. Frolich ED. Hemodynamics and other determinants in development of left ventricular hypertrophy. Federal Proceedings 1983; 42: 2709–15

    Google Scholar 

  35. Frolich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol 1979; 44: 959–63

    Article  Google Scholar 

  36. Devereux RB, Savage DD, Drayer JIM, et al. Left ventricular hypertrophy and function in high, normal, and low-renin forms of essential hypertension. Hypertension 1982; 4: 524–31

    Article  PubMed  CAS  Google Scholar 

  37. Sen S, Tarazi RC. Regression of myocardial hypertrophy and influence of adrenergic system. Am J Physiol 1983; 244: H766–84

    Google Scholar 

  38. Jin M, Wilhelm MJ, Lang RE, et al. Endogenous tissue reninangiotensin system: from molecular biology to therapy. Am J Med 1988; 84 Suppl. 3A: 28–36

    Article  PubMed  CAS  Google Scholar 

  39. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin system. Circulation 1991; 83: 1849–65

    Article  PubMed  CAS  Google Scholar 

  40. Jackson TR, Blair LAC, Marshall J, et al. The mas oncogene encodes an angiotensin receptor. Nature 1988; 335: 437–40

    Article  PubMed  CAS  Google Scholar 

  41. Katan M, Parker PJ. Oncogenes and cell control. Nature 1988; 332: 203

    Article  PubMed  CAS  Google Scholar 

  42. Simpson PC. Proto-oncogenes and cardiac hypertrophy. Annual Review of Physiology 1989; 51: 189–202

    Article  PubMed  CAS  Google Scholar 

  43. Weinberg RA. The action of oncogenes in the cytoplasm and nucleus. Science 1985; 230: 770–6

    Article  PubMed  CAS  Google Scholar 

  44. Kromer EP, Brundobler M, Hennig V, et al. Effect of converting enzyme inhibition on myocardial hypertrophy and its regression in experimental aortic stenosis in the rat. Circulation 1987; 76 Suppl. IV: IV33

    Google Scholar 

  45. Neyes L, Nouskas J, Oberdorf S, et al. Effect of quinapril on myocardial early gene expression and protein synthesis induced by endothelin-1. Eur Heart J 1991; 12 Suppl.: 36

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Associazione Riva-Rocci per lo Studio e la Cura della Ipertensione Arteriosa, Vercelli, Italy

    G. Lavezzaro

  2. Medical & Scientific Affairs, Parke-Davis SpA, Via Colombo 1, 20020, Lainate (MI), Italy

    Gino Raule, R. Toppi & S. Gasparrini

Authors
  1. G. Lavezzaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gino Raule
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Toppi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Gasparrini
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Riva-Rocci Association

Additional information

Participating Centres are listed on page 47.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lavezzaro, G., Riva-Rocci Association., Raule, G. et al. Angiotensin Converting Enzyme Inhibition with Quinapril and Left Ventricular Mass in the Hypertensive Patient. Drug Invest 8, 38–48 (1994). https://doi.org/10.1007/BF03257425

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03257425

Keywords

Search

Navigation